登录

Targeting One Announces ¥150 Million Series B Financing

作者: Mailman 2021-01-18 17:28
新羿生物
http://www.targetingone.com/
企业数据由 动脉橙 提供支持
体外诊断产品研发商 | B+轮 | 运营中
中国-北京
2024-02-20
融资金额:近亿人民币
盛迪私募
查看

(VCBeat) Jan 8, 2021 -- Targeting One, a top player in the digital PCR market, recently announced it has closed ¥150 million in Series B funding. The investment was led by Lilly Asia Ventures, with participation from China Growth Capital, GL Ventures, and existing investors Qingdao Yufeng and Zhongyuan Huichen.


The investment will enable Targeting One to further develop its digital PCR platform, accelerate the development and clinical trials of several reagents for molecular diagnostics, promote the and application of digital PCR tools in the life science and clinical fields. 


With the increasing demand for liquid biopsies and early screening of tumors, early diagnosis of infectious diseases, rapid diagnosis of severe infections and non-invasive screening of birth defects, digital PCR, as a breakthrough "third-generation PCR technology", has a huge market size. It has the advantages of single-molecule sensitivity, strong anti-interference ability, simple operation and easy standardization, and can provide precise absolute quantitative analysis. Digital PCR is one of the most competitive next-generation technology of molecular diagnostics, and large international companies have developed related business in this sector one after another.


Targeting One has an excellent R&D team, a complete intellectual property system, a highly competitive digital PCR platform and excellent commercialization capability. The company has rapidly built up a product line covering tumor fluid biopsy, early screening of tumors, early diagnosis of infectious diseases, rapid diagnosis of severe infections and birth defects, and other major diseases.


>>>>

About China Growth Capital (CGC)


CGC is a China-focused seed and early venture investor since 2006. The firm funds seed to Series B in enterprise software and services, frontier technologies, marketplace, and consumer sectors. The typical investment size ranges from $1M to 5M with a hard cap ceiling at $15M per company. CGC manages 8 Billion RMB (approximately $1.2 billion) across its different RMB and USD funds.


>>>>

About GL Ventures


GL Ventures was set up by private equity heavyweight Hillhouse Capital to invest in emerging startups in February 2020. GL Ventures focuses on four areas: biomedicine and medical devices, software services and initiatives in tech innovations, consumer internet and technology, and emerging consumer brands and services.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

Bestopmed Scores Millions of Yuan in Angel Round of Financing

AnchorDx Secured $40M in Series C Round of Financing

AcornMed Closes on ¥100M Series A Round of Financing

Targene Biotech Raises ¥100M in Series A Financing, Focusing on Early Diagnosis of Tumor

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

He-man Gene Announces Closing Angel Round of Millions of RMB

2021-01-18
下一篇

Huoshi Chuangzao Secures ¥100M in Series A Funding

2021-01-18